TRLV // Trulieve Cannabis Corp. Subordinate Voting Shares
FA <GO> NYSE RQD COCKPIT → CIK 0001754195 ↗ Health Care • Medicinal Chemicals and Botanical Products
$10.28 ▼ -0.32
(-3.02%)
MKT CAP: $2.04B • VOL: 1.41M
52W L $5 52W H $13
TRLV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.18B | $1.19B | $1.13B |
| YoY Revenue Growth % | -0.4% | +5.1% | — |
| Gross Profit | $711.2M | $715.7M | — |
| Gross Margin % | 60.2% | 60.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $143.5M | $97.8M | -$221.6M |
| Operating Margin % | 12.1% | 8.2% | -19.6% |
| Net Income (GAAP) | -$116.4M | -$155.1M | -$526.8M |
| EBITDA (Normalized) | $178.8M | $195.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $272.8M | $271.5M | $201.8M |
| Capital Expenditures (CapEx) | $44.2M | $122.6M | — |
| Free Cash Flow (FCF) | $228.6M | $148.9M | $201.8M |
| FCF Margin % | 19.4% | 12.5% | 17.9% |
| Return on Invested Capital (ROIC %) | 12.8% | 7.6% | — |
| Cash & Short-Term Equivalents | $255.5M | $238.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.14B | $1.25B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TRLV.